Skip to main content Accessibility help
×
×
Home

The health and economic burden of chickenpox and herpes zoster in Belgium

  • J. BILCKE (a1), B. OGUNJIMI (a1) (a2), C. MARAIS (a1), F. DE SMET (a3) (a4), M. CALLENS (a3), K. CALLAERT (a5), E. VAN KERSCHAVER (a6), J. RAMET (a2), P. VAN DAMME (a1) and P. BEUTELS (a1)...

Summary

Varicella-zoster virus causes chickenpox (CP) and after reactivation herpes zoster (HZ). Vaccines are available against both diseases warranting an assessment of the pre-vaccination burden of disease. We collected data from relevant Belgian databases and performed five surveys of CP and HZ patients. The rates at which a general practitioner is visited at least once for CP and HZ are 346 and 378/100 000 person-years, respectively. The average CP and HZ hospitalization rates are 5·3 and 14·2/100 000 person-years respectively. The direct medical cost for HZ is about twice as large as the direct medical cost for CP. The quality-adjusted life years lost for ambulatory CP patients consulting a physician is more than double that of those not consulting a physician (0·010 vs. 0·004). In conclusion, both diseases cause a substantial burden in Belgium.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The health and economic burden of chickenpox and herpes zoster in Belgium
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      The health and economic burden of chickenpox and herpes zoster in Belgium
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      The health and economic burden of chickenpox and herpes zoster in Belgium
      Available formats
      ×

Copyright

Corresponding author

*Author for correspondence: Dr J. Bilcke, Center for Health Economic Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. (Email: joke.bilcke@ua.ac.be)

References

Hide All
1. Gershon, A, Takahashi, M, Seward, J. Varicella vaccine. In: Plotkin, SA, Orenstein, W, Offit, P, eds. Vaccines . Pennsylvania: Saunders Company, 2004, pp. 783823.
2. Hope-Simpson, RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proceedings of the Royal Society of Medicine 1965; 58: 9–20.
3. Annemans, L, et al. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. Journal of Medical Economics 2010; 13: 537551.
4. Arvin, AM, Koropchak, CM, Wittek, AE. Immunological evidence of reinfection with varicella-zoster virus. Journal of Infectious Diseases 1983; 148: 200205.
5. Ogunjimi, B, et al. Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents. Viral Immunology 2011; 24: 151157.
6. Vossen, MTM, et al. Development of virus-specific CD4(+) T cells on reexposure to varicella-zoster virus. Journal of Infectious Diseases 2004; 190: 7282.
7. Jumaan, AO, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. Journal of Infectious Diseases 2005; 191: 20022007.
8. Leung, J, et al. Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clinical Infectious Diseases 2011; 52: 332340.
9. Nelson, MR, Britt, HC, Harrison, CM. Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Medical Journal of Australia 2010; 193: 110113.
10. Yih, WK, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health 2005; 5: 68.
11. Brisson, M, et al. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20: 25002507.
12. Gershon, AA, et al. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. Journal of Infectious Diseases 1996; 173: 450453.
13. Thomas, SL, Wheeler, JG, Hall, AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360: 678682.
14. Bilcke, J, et al. Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium. Brussels: Belgian Health Care Knowledge Centre (KCE), 2011.
15. van Hoek, AJ, et al. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine 2011; 29: 24112420.
16. Brisson, M, Edmunds, WJ. Varicella vaccination in England and Wales: cost-utility analysis. Archives of Disease in Childhood 2003; 88: 862869.
17. Van Casteren, V, Bossuyt, N.Survey site visit Belgium 15 July 2002. Belgian Sentinel Network of General Practitioners, 2002.
18. Zebra Zone European Research & Service Center. Absenteeism in Belgium 2006 (http://www.securex.eu/be/website/be/public/0ECE524AE5E24507C125729100465452_nl/0ECE524AE5E24507C125729100465452_04_nl.pdf). Accessed 7 December 2011.
19. Vrijens, F, et al. Nosocomial infections in Belgium, part 2: impact on mortality and costs. Brussels: Belgian Health Care Knowledge Centre (KCE), 2009.
20. Oxman, MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine 2005; 352: 22712284.
21. Coplan, PM, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. Journal of Pain 2004; 5: 344356.
22. Brisson, M, Edmunds, WJ. Epidemiology of varicella-zoster virus in England and Wales. Journal of Medical Virology 2003; 70 (Suppl. 1): S9–14.
23. Coplan, P, et al. Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. Pediatric Infectious Disease Journal 2001; 20: 641645.
24. Brisson, M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiology and Infection 2001; 127: 305314.
25. Smith, KJ, Roberts, MS. Cost effectiveness of vaccination strategies in adults without a history of chickenpox. American Journal of Medicine 2000; 108: 723729.
26. Sackett, DL, Torrance, GW. The utility of different health states as perceived by the general public. Journal of Chronic Diseases 1978; 31: 697704.
27. Merrett, P, et al. Strategies to prevent varicella among newly arrived adult immigrants and refugees: A cost-effectiveness analysis. Clinical Infectious Diseases 2007; 44: 10401048.
28. Drolet, M, et al. A prospective study of the herpes zoster severity of illness. Clinical Journal of Pain 2010; 26: 656666.
29. Scott, FT, et al. The burden of herpes zoster: a prospective population based study. Vaccine 2006; 24: 13081314.
30. Opstelten, W, et al. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain 2007; 132 (Suppl. 1): S52–9.
31. Drolet, M, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Canadian Medical Association Journal 2010; 182: 17311736.
32. Yawn, BP, et al. Herpes zoster recurrences more frequent than previously reported. Mayo Clinic Proceedings 2011; 86: 8893.
33. Wareham, DW, Breuer, J. Herpes zoster. British Medical Journal 2007; 334: 12111215.
34. Wootton, SH, et al. The epidemiology of children hospitalized with herpes zoster in Canada: Immunization Monitoring Program, Active (IMPACT), 1991–2005. Pediatric Infectious Disease Journal 2008; 27: 112118.
35. Insinga, RP, IItzler, RF, Pellissier, JM. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 2007; 25: 155169.
36. White, RR, et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics 2009; 27: 781792.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed